Breakthrough Designation
Breakthrough Designation in ALL, HIFU FDA Approval, Breast Cancer Screening Update, and More


Gina Columbus reports on a breakthrough therapy designation for inotuzumab ozogamicin for acute lymphoblastic leukemia, FDA clearance for high-intensity focused ultrasound for prostate cancer, and updates to the American Cancer Society’s breast cancer screening guidelines for those at average risk.

LOGO 3

Focused ultrasound therapy uses ultrasound waves to guide the application of focused, high-intensity ultrasound waves through the skin down to the target tissue.

Contact Us

NUTAS
Breast Conservancy Therapy Centre
GD-21 Opp. Pillar No.368
Metro Stn. Pitampura, Delhi-110034
Ph.011-46241164 / 23858972 / 9810284657 / 9958047250
E.mail : infonutas@gmail.com

© 2013-17 NUTAS - All Rights Reserved.| Developed by AGM Search India